---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-008868"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:44:42.205917+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aethlon Hemopurifier removes 99% of H5N1 in vitro; monitoring bird flu outbreak

## Summary
- In vitro study with scaled-down Hemopurifier showed 99% removal of H5N1 virus after 6 hours.
- Device has not yet been used in human patients for H5N1; 38 patients treated for other enveloped viruses.
- Hemopurifier holds FDA breakthrough device designation for life-threatening viruses with no effective treatment.
- Company monitoring cases and engaging with hospitals, California, and FDA on potential use.
- CDC recommends antivirals for H5N1; resistance observed in some hospitalized patients, suggesting need for novel therapies.

## SEC filing metadata
- accession: 0001683168-24-008868
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824008868/0001683168-24-008868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824008868/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-008868
- JSON: https://secwatch.observer/filing/0001683168-24-008868.json
- Plain text: https://secwatch.observer/filing/0001683168-24-008868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.